Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ACCESS (phase 2b)

ACCESS (phase 2b)

Aleniglipron · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Aleniglipron
Population
obesity
Phase
2
Participants
65
Duration
36 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
aleniglipron 45 mgobesity3645−9.0 % vs −0.8 %
Δ −8.2 pp
−8.8 % vs −1.0 %
Δ −7.8 pp
−0.3 vs +0.013.3 vs 5.426.7 vs 25.071.1 vs 21.440.0 vs 5.42.2 vs 5.4−7.9 vs −1.5verified
aleniglipron 90 mgobesity3665−10.7 % vs −0.8 %
Δ −9.9 pp
−10.2 % vs −1.0 %
Δ −9.2 pp
−0.3 vs +0.07.7 vs 5.424.6 vs 25.067.7 vs 21.444.6 vs 5.40.0 vs 5.4−8.9 vs −1.5verified
aleniglipron 120 mgobesity3664−12.1 % vs −0.8 %
Δ −11.3 pp
−11.4 % vs −1.0 %
Δ −10.4 pp
−0.4 vs +0.011.1 vs 5.421.9 vs 25.065.1 vs 21.431.7 vs 5.46.3 vs 5.4−9.0 vs −1.5verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (27)
  • aleniglipron 45 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
    across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
  • aleniglipron 45 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
    Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
  • aleniglipron 45 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
    Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
  • aleniglipron 45 mg · disc_any · Fig. 1 CONSORT
    33 (73.3%) Completed treatment (week 36) 12 (26.7%) Discontinued study treatment 6 (13.3%) Adverse event
  • aleniglipron 45 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
    Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
  • aleniglipron 45 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
    Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
  • aleniglipron 45 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
    Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
  • aleniglipron 45 mg · hba1c · Extended Data Table 5
    Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
  • aleniglipron 45 mg · sbp · Extended Data Table 5
    Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
  • aleniglipron 90 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
    across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
  • aleniglipron 90 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
    Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
  • aleniglipron 90 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
    Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
  • aleniglipron 90 mg · disc_any · Fig. 1 CONSORT
    16 (24.6%) Discontinued study treatment 5 (7.7%) Adverse event
  • aleniglipron 90 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
    Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
  • aleniglipron 90 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
    Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
  • aleniglipron 90 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
    Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
  • aleniglipron 90 mg · hba1c · Extended Data Table 5
    Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
  • aleniglipron 90 mg · sbp · Extended Data Table 5
    Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)
  • aleniglipron 120 mg · weight_eff · Results, Primary outcomes (also Fig. 3a/b)
    across all aleniglipron doses in the efficacy estimand. The least squares (LS) mean change in body weight from baseline to week 36 with aleniglipron was −9.0% for 45 mg (95% confidence interval (CI), −11.2 to −6.8%), −10
  • aleniglipron 120 mg · weight_tp · Extended Data Table 2 (N in header: 45/65/63/56)
    Extended Data Table 2 | Body weight reduction from baseline at Week 36 (treatment estimand) Aleniglipron 45 mg (N=45) Aleniglipron 90 mg (N=65) Aleniglipron 120 mg (N=63) Pooled placebo (N=56) Percent change in body weig
  • aleniglipron 120 mg · ae_dc · Table 2 (safety analysis set, baseline to week 36); columns
    Any TEAE leading to discontinuation of treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4)
  • aleniglipron 120 mg · disc_any · Fig. 1 CONSORT
    14 (21.9%) Discontinued study treatment 7 (10.9%) Adverse event
  • aleniglipron 120 mg · nausea · Table 2 (safety analysis set, baseline to week 36); columns
    Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4)
  • aleniglipron 120 mg · vomiting · Table 2 (safety analysis set, baseline to week 36); columns
    Vomiting 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4)
  • aleniglipron 120 mg · sae · Table 2 (safety analysis set, baseline to week 36); columns
    Any SAEs 1 (2.2) 0 (0.0) 4 (6.3) 3 (5.4)
  • aleniglipron 120 mg · hba1c · Extended Data Table 5
    Hemoglobin A1C (%) -0.27 (0.047) (-0.363, -0.178) -0.32 (0.039) (-0.395, -0.241) -0.36 (0.039) (-0.434, -0.280) 0.01 (0.042) (-0.070, 0.098)
  • aleniglipron 120 mg · sbp · Extended Data Table 5
    Systolic blood pressure (mmHg) -7.9 (1.71) (-11.25, -4.48) -8.9 (1.42) (-11.68, -6.07) -9.0 (1.40) (-11.74, -6.21) -1.5 (1.52) (-4.49, 1.49)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ACCESS (phase 2b). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/access/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.